Beschreibung
Bupropion, a CYP2D6 inhibitor, significantly increases aripiprazole plasma concentrations, increasing the risk of dose-dependent adverse effects.
Mechanismus
Bupropion inhibits CYP2D6 moderately to potently, reducing aripiprazole metabolism and raising its AUC; the active metabolite dehydro-aripiprazole ratio also shifts.
Klinische Bedeutung
Aripiprazole exposure may increase substantially; adverse effects (akathisia, metabolic effects) may become clinically prominent.
Maßnahmen
Reduce aripiprazole dose when adding bupropion; monitor for adverse effects and adjust dose based on clinical response.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.